Johnson & Johnson $JNJ Holdings Lifted by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. raised its position in Johnson & Johnson (NYSE:JNJ) by 2.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 933,393 shares of the company’s stock after purchasing an additional 20,208 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of Mn Services Vermogensbeheer B.V.’s investment portfolio, making the stock its 12th biggest holding. Mn Services Vermogensbeheer B.V.’s holdings in Johnson & Johnson were worth $193,166,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. AustralianSuper Pty Ltd raised its position in shares of Johnson & Johnson by 632.0% during the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock worth $16,536,000 after buying an additional 77,000 shares in the last quarter. J.W. Cole Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 2.2% in the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after acquiring an additional 2,769 shares in the last quarter. Guinness Asset Management LTD increased its stake in shares of Johnson & Johnson by 0.4% during the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after acquiring an additional 5,994 shares during the period. Treasurer of the State of North Carolina raised its holdings in Johnson & Johnson by 8.3% during the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after purchasing an additional 94,957 shares in the last quarter. Finally, National Pension Service raised its holdings in Johnson & Johnson by 3.2% during the third quarter. National Pension Service now owns 4,926,569 shares of the company’s stock worth $913,484,000 after purchasing an additional 151,707 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,142 shares of company stock worth $7,360,528 in the last three months. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

NYSE JNJ opened at $244.20 on Thursday. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The business’s fifty day moving average is $238.92 and its two-hundred day moving average is $212.08. The stock has a market capitalization of $588.19 billion, a P/E ratio of 22.10, a P/E/G ratio of 2.42 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research reports. Morgan Stanley set a $253.00 price target on Johnson & Johnson in a research note on Wednesday, March 18th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $255.00 target price on shares of Johnson & Johnson in a research note on Monday. Wolfe Research boosted their price target on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th. Finally, Citigroup upped their price target on shares of Johnson & Johnson from $250.00 to $274.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $236.91.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval / commercial launch catalyst — J&J’s new oral psoriasis drug ICOTYDE (icotrokinra) has FDA approval and encouraging 52?week data, offering a near?term product growth story that could boost immunology sales and investor sentiment. Will ICOTYDE’s First?in?Class Oral Psoriasis Launch Redefine Johnson & Johnson’s (JNJ) Immunology Narrative?
• Positive Sentiment: Analyst support — Royal Bank of Canada reiterated an “Outperform” rating, providing third?party validation that can support institutional demand. Royal Bank Of Canada Reaffirms “Outperform” Rating for Johnson & Johnson (NYSE:JNJ)
• Positive Sentiment: Earnings momentum — Multiple writeups note J&J’s strong earnings?surprise history and argue the company has the ingredients to beat again, a tailwind for the stock into the next report. Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Pipeline and valuation debate — Analysts and commentators are re?examining J&J’s pipeline and dividend pedigree (Seeking Alpha, 247WallSt pieces). These arguments support a buy?and?hold case but leave room for differing valuations after the recent rally. Johnson & Johnson: Is The Stock Still Undervalued After The Rally? A Quantitative Approach
• Neutral Sentiment: Investor interest / trending coverage — Zacks and other outlets note higher retail/investor attention and discuss J&J as a trending defensive/dividend name amid market volatility; this increases liquidity but not necessarily directional conviction. Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Bridgewater trimming — Billionaire Ray Dalio’s Bridgewater reduced its J&J stake, which can signal cautious positioning by large funds and pressure headline sentiment despite the holding being long?term. Johnson & Johnson (JNJ): Billionaire Ray Dalio Trims Position
• Negative Sentiment: Legal/media overhang — Continued media discussion (including Jim Cramer coverage) about prior lawsuits and the stock’s “free fall / rise” dynamic keeps a legal risk premium in place for some investors. Jim Cramer Highlights Johnson & Johnson Stock’s “Free Fall” and Rise Despite Lawsuits

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.